Nicholas R Medjeral-Thomas
Overview
Explore the profile of Nicholas R Medjeral-Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong E, Nester C, Cavero T, Karras A, le Quintrec M, Lightstone L, et al.
Kidney Int Rep
. 2023 Dec;
8(12):2754-2764.
PMID: 38106570
Introduction: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability,...
2.
Lomax-Browne H, Medjeral-Thomas N, Barbour S, Gisby J, Han H, Bomback A, et al.
Clin J Am Soc Nephrol
. 2022 Jul;
17(7):994-1007.
PMID: 35777834
Background And Objectives: C3 glomerulopathy and idiopathic Ig-associated membranoproliferative GN are kidney diseases characterized by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of...
3.
4.
Medjeral-Thomas N, Troldborg A, Hansen A, Pihl R, Clarke C, Peters J, et al.
Oxf Open Immunol
. 2021 Aug;
2(1):iqab014.
PMID: 34458849
Protease inhibitors influence a range of innate immunity and inflammatory pathways. We quantified plasma concentrations of key anti-inflammatory protease inhibitors in chronic haemodialysis patients with coronavirus disease 2019 (COVID-19). The...
5.
Medjeral-Thomas N, Cook H, Pickering M
Semin Immunopathol
. 2021 Aug;
43(5):679-690.
PMID: 34379175
IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing...
6.
Medjeral-Thomas N, Pusey C
Clin J Am Soc Nephrol
. 2021 Aug;
16(8):1149-1151.
PMID: 34362782
No abstract available.
7.
Dotz V, Visconti A, Lomax-Browne H, Clerc F, Hipgrave Ederveen A, Medjeral-Thomas N, et al.
J Am Soc Nephrol
. 2021 Jun;
32(10):2455-2465.
PMID: 34127537
Background: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and is a leading cause of renal failure. The disease mechanisms are not completely understood, but a higher...
8.
Medjeral-Thomas N, Troldborg A, Hansen A, Gisby J, Clarke C, Prendecki M, et al.
Front Immunol
. 2021 May;
12:671052.
PMID: 33995410
We do not understand why non-white ethnicity and chronic kidney disease increase susceptibility to COVID-19. The lectin pathway of complement activation is a key contributor to innate immunity and inflammation....
9.
Medjeral-Thomas N, Pickering M, Cook H
Curr Opin Nephrol Hypertens
. 2021 Mar;
30(3):310-316.
PMID: 33767058
Purpose Of Review: In this review, we discuss recent studies showing the importance of the complement pathway in kidney disease. Recent Findings: Recent findings in C3 glomerulopathy (C3G) include: acute...
10.
Medjeral-Thomas N, Thomson T, Ashby D, Muthusamy A, Nevin M, Duncan N, et al.
Kidney Int Rep
. 2020 Sep;
5(11):2055-2065.
PMID: 32864514
Background: Dialysis patients are at risk of severe coronavirus disease 2019 (COVID-19). We managed COVID-19 hemodialysis outpatients in dedicated satellite dialysis units. This provided rare opportunity to study early disease...